Navtemadlin and Ruxolitinib for Myelofibrosis: Study Participation Information

ClinicalTrials.gov identifier: NCT06479135

This Phase 3 clinical study evaluates navtemadlin plus ruxolitinib versus placebo plus ruxolitinib in myelofibrosis with a suboptimal response to ruxolitinib.

Study availability and enrollment status may change. A California Research Institute coordinator can confirm current local availability and explain the screening process.

Request study information